Cargando…
Role of perioperative immunotherapy in localized renal cell carcinoma
Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at...
Autores principales: | Kaur, Jasmeet, Patil, Goutham, Geynisman, Daniel M., Ghatalia, Pooja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387776/ https://www.ncbi.nlm.nih.gov/pubmed/37529159 http://dx.doi.org/10.1177/17588359231181497 |
Ejemplares similares
-
Role of immunotherapy in localized muscle invasive urothelial cancer
por: Kaur, Jasmeet, et al.
Publicado: (2021) -
The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013–2016 from the ClinicalTrials.gov Website
por: Ghatalia, Pooja, et al.
Publicado: (2017) -
Approved checkpoint inhibitors in bladder cancer: which drug should
be used when?
por: Ghatalia, Pooja, et al.
Publicado: (2018) -
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022) -
Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)
por: Ghatalia, Pooja, et al.
Publicado: (2018)